Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing significant amendments to its credit and receivables agreements, effective February 7, 2017. The company has entered into a Second Amended and Restated Credit and Security Agreement, extending its credit facility's term to February 7, 2019, and increasing the aggregate commitments by $400,000,000. This move enhances the company's financial flexibility and borrowing capacity. Additionally, BSX amended its Receivables Sale Agreement, primarily to incorporate previous amendments and make technical adjustments. These actions reflect the company's proactive approach to managing its capital structure and ensuring adequate liquidity to support its ongoing operations and strategic initiatives. Investors should view these amendments as a positive development, indicating financial stability and readiness for future growth.
Key Highlights
- 1Boston Scientific Corporation (BSX) entered into a Second Amended and Restated Credit and Security Agreement effective February 7, 2017.
- 2The credit facility term has been extended through February 7, 2019.
- 3Aggregate commitments under the credit facility have been increased to $400,000,000.
- 4The agreement allows for extending credit directly or through conduits.
- 5It also permits LIBOR loans referencing the Libor Market Index Rate.
- 6A Second Amended and Restated Receivables Sale Agreement was also executed, incorporating prior amendments and technical changes.
- 7These agreements aim to enhance financial flexibility and liquidity for the company.